Share
array:24 [ "pii" => "S2173579422000858" "issn" => "21735794" "doi" => "10.1016/j.oftale.2022.06.001" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "2003" "copyright" => "Sociedad Española de Oftalmología" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Arch Soc Esp Oftalmol. 2022;97:464-72" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0365669122000764" "issn" => "03656691" "doi" => "10.1016/j.oftal.2022.02.003" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "2003" "copyright" => "Sociedad Española de Oftalmología" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Arch Soc Esp Oftalmol. 2022;97:464-72" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Revisión de la literatura sobre la evidencia disponible actualmente para el manejo de las queratitis infecciosas con PACK-CXL" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "464" "paginaFinal" => "472" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Review of the literature on the currently available evidence for the management of infectious keratitis with PACK-CXL" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S.M. Hamida Abdelkader, M. Rodríguez Calvo-de-Mora, J.A. Gegúndez-Fernández, F.L. Soler-Ferrández, C. Rocha-de-Lossada" "autores" => array:5 [ 0 => array:2 [ "nombre" => "S.M." "apellidos" => "Hamida Abdelkader" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Rodríguez Calvo-de-Mora" ] 2 => array:2 [ "nombre" => "J.A." "apellidos" => "Gegúndez-Fernández" ] 3 => array:2 [ "nombre" => "F.L." "apellidos" => "Soler-Ferrández" ] 4 => array:2 [ "nombre" => "C." "apellidos" => "Rocha-de-Lossada" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173579422000858" "doi" => "10.1016/j.oftale.2022.06.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173579422000858?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365669122000764?idApp=UINPBA00004N" "url" => "/03656691/0000009700000008/v1_202207300625/S0365669122000764/v1_202207300625/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173579422000184" "issn" => "21735794" "doi" => "10.1016/j.oftale.2021.05.003" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1989" "copyright" => "Sociedad Española de Oftalmología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Arch Soc Esp Oftalmol. 2022;97:473-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Short communication</span>" "titulo" => "Trocar shortening for pediatric vitreoretinal surgery with a 3D printed trocar spacer: Report of two cases" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "473" "paginaFinal" => "476" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Espaciador de trocares para cirugía vitreorretiniana pediátrica utilizando una impresora 3D: reporte de 2 casos" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1254 "Ancho" => 1258 "Tamanyo" => 165398 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Cannula-trocar system 27-gauge.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Di-Luciano, R. Gómez-Nuñez, F. Acosta, L. Rivas-Vega, V. Morales-Cantón, M. Trujillo-Alvarez, L. Cernichiaro-Espinosa" "autores" => array:7 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Di-Luciano" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Gómez-Nuñez" ] 2 => array:2 [ "nombre" => "F." "apellidos" => "Acosta" ] 3 => array:2 [ "nombre" => "L." "apellidos" => "Rivas-Vega" ] 4 => array:2 [ "nombre" => "V." "apellidos" => "Morales-Cantón" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Trujillo-Alvarez" ] 6 => array:2 [ "nombre" => "L." "apellidos" => "Cernichiaro-Espinosa" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0365669122000314" "doi" => "10.1016/j.oftal.2021.05.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365669122000314?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173579422000184?idApp=UINPBA00004N" "url" => "/21735794/0000009700000008/v1_202207300614/S2173579422000184/v1_202207300614/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173579422000561" "issn" => "21735794" "doi" => "10.1016/j.oftale.2022.03.010" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1993" "copyright" => "Sociedad Española de Oftalmología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Soc Esp Oftalmol. 2022;97:457-63" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Results of large macular hole surgery using different interposition techniques. A report on 9 cases" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "457" "paginaFinal" => "463" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Resultados de la cirugía de agujero macular grande empleando distintas técnicas de interposición macular. Serie de 9 casos" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1033 "Ancho" => 1500 "Tamanyo" => 287623 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Preoperative tomographic images of the patients. A: FIILM group. B: MLI folded group. C: MH graft group. D: CA autogenous graft group.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Galletero Pandelo, H. Olaso Fernández, J.A. Sánchez Aparicio, C. Rodríguez Vidal, N. Martínez-Alday" "autores" => array:5 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Galletero Pandelo" ] 1 => array:2 [ "nombre" => "H." "apellidos" => "Olaso Fernández" ] 2 => array:2 [ "nombre" => "J.A." "apellidos" => "Sánchez Aparicio" ] 3 => array:2 [ "nombre" => "C." "apellidos" => "Rodríguez Vidal" ] 4 => array:2 [ "nombre" => "N." "apellidos" => "Martínez-Alday" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0365669122000363" "doi" => "10.1016/j.oftal.2021.12.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365669122000363?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173579422000561?idApp=UINPBA00004N" "url" => "/21735794/0000009700000008/v1_202207300614/S2173579422000561/v1_202207300614/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Review of the literature on the currently available evidence for the management of infectious keratitis with PACK-CXL" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "464" "paginaFinal" => "472" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "S.M. Hamida Abdelkader, M. Rodríguez Calvo-de-Mora, J.A. Gegúndez-Fernández, F.L. Soler-Ferrández, C. Rocha-de-Lossada" "autores" => array:5 [ 0 => array:4 [ "nombre" => "S.M." "apellidos" => "Hamida Abdelkader" "email" => array:1 [ 0 => "smha.ard@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "M." "apellidos" => "Rodríguez Calvo-de-Mora" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "J.A." "apellidos" => "Gegúndez-Fernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "F.L." "apellidos" => "Soler-Ferrández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "C." "apellidos" => "Rocha-de-Lossada" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] ] "afiliaciones" => array:7 [ 0 => array:3 [ "entidad" => "Complejo Hospitalario Universitario Torrecárdenas, Almería, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hospital Regional Universitario de Málaga, Málaga, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hospital Clínico San Carlos, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Innova Ocular Clínica Dr. Soler, Elche, Alicante, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Departamento de Oftalmología (Qvision), Hospital Vithas Vírgen del Mar, Almería, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Hospital Universitario Vírgen de las Nieves, Granada, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Universidad de Sevilla, Departamento de Cirugía, Área de Oftalmología, Sevilla, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Revisión de la literatura sobre la evidencia disponible actualmente para el manejo de las queratitis infecciosas con PACK-CXL" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Infectious keratitis (IK) is an important cause of visual loss worldwide, particularly in developing countries, and may be the result of minor ocular trauma combined with poor hygiene.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a> Although the incidence rate in industrialised countries is significantly lower, IK can arise from contact lens wear, dry eye, recent ocular surgery or systemic immunosuppression.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a> The use of broad-spectrum antibiotics (ATBs) can achieve microbiological eradication of the causative pathogens.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,3</span></a> The massive and widespread use of broad-spectrum ATBs has led to an increase in antimicrobial resistance (AMR).<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,4</span></a> The progressive decrease in the effectiveness of ATBs leads to the appearance of complications such as corneal scarring,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> endophthalmitis, corneal thinning or perforation,<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a> or the need for “hot” surgical therapeutic keratoplasties, such as penetrating keratoplasty (PK) or deep anterior lamellar keratoplasty, which increase the rate of graft rejection.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8–10</span></a> Therefore, there is a need for novel approaches to deal with IK, improving microbial eradication with fewer side effects such as corneal cross-linking (CXL).<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,11</span></a> CXL is a technique developed in the 1990s for the treatment of corneal ectatic disorders such as keratoconus (KC). In 2003 the first article using CXL to stop the progression of KC was published.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> In recent years, the use of CXL in IK has been proposed<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11,12</span></a> because of the ATM properties of the photoactivated chromophore (riboflavin [RB]) and ultraviolet (UV)-A light,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> which could reduce pathogens and increase the resistance of corneal tissue to enzymatic degradation.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Thus, to distinguish the use of CXL for the treatment of IK from CXL for the management of progressive KC, the term PACK-CXL (photoactivated chromophore for corneal CXL in the treatment of IKs) was created at the ninth CXL congress in Dublin, Ireland, in 2013.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> Its mechanism of action includes, among others, inhibition of microbial replication, RNA and DNA damage and direct damage of pathogen cell walls.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> The number of publications reporting on CXL treatment of IK is increasing, so that it could become a new alternative to standard ATB treatment of IK in the future.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> The aim of the present study is to conduct a literature review on the efficacy and safety outcomes of PACK-CXL in IC, based on the currently available scientific evidence.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Methodology</span><p id="par0010" class="elsevierStylePara elsevierViewall">The literature search focused on retrieving comparative studies on the efficacy and safety of PACK-CXL for the treatment of IK. This search was conducted in the following databases: Cochrane Library, PubMed, EMBASE, Web of Science, Ovid MEDLINE and Scopus.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Corneal cross-linking</span><p id="par0015" class="elsevierStylePara elsevierViewall">CXL for the management of corneal ectasia was first published in 2003 by Wollensak et al. in order to stabilise the progression of KC.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> In this technique, a combination of 370<span class="elsevierStyleHsp" style=""></span>nm<span class="elsevierStyleHsp" style=""></span>UV-A (320−400<span class="elsevierStyleHsp" style=""></span>nm) and a photosensitising agent, RB, is used to increase the biomechanical stability and stiffness of the cornea.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,4</span></a> CXL has recently been used for the management of IK. The rationale for such use is based on the inherent strong ATM activity of UV light, which can directly damage DNA and RNA of various types of microorganisms.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> In addition, reactive oxygen species released by photoactivated RB (these reactive species are generated when a photosensitiser, such as RB, is irradiated with UV-A in the presence of oxygen)<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> can directly affect DNA, cell membranes of micro-organisms, membrane-bound protein complexes, plasma membrane, lipids and nucleic acids, culminating in a powerful synergistic ATM action.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,4,11</span></a> Among the potential advantages of the application of UV-A light and RB over ATBs is the ability to decrease toxicity on the ocular surface and avoid adherence problems associated with the need for frequent topical treatment.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> The sum of these effects, together with increased corneal stiffness and resistance to proteolytic enzymatic digestion of corneal stromal collagen, have made CXL an attractive adjuvant in the treatment of IK.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">However, PACK-CXL is not commonly used in daily clinical practice due to uncertainty about its efficacy and safety.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> This is mainly attributed to the wide heterogeneity of the literature in relation to patient cohort, causative microorganisms, ulcer characteristics and severity, treatment protocol and the lack of large randomised clinical trials (RCTs) to support it.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Post-CXL neurotoxicity</span><p id="par0025" class="elsevierStylePara elsevierViewall">Analysis of corneal nerve fibres by confocal microscopy has shown a loss of nerve fibres (immediate<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> or at one month<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a>) from the subepithelial plexus, with apoptosis of mid-anterior stromal keratocytes, with basal restoration at 6 months post-CXL and no morphological changes at 1, 3 and 6 months post-CXL in the posterior stroma<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,16</span></a> after standard CXL (CXL-S) and accelerated transepithelial CXL (CXL-TE-A) at 45<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Regeneration of the subepithelial plexus fibres occurred with rapid growth from the surrounding non-irradiated area between 2 and 3 months postoperatively,<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,16</span></a> with a return to baseline corneal sensitivity values at 6–12 months postoperatively.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,16</span></a> However, confocal microscopy has not demonstrated loss of nerve fibres from the subepithelial plexus and mid-anterior stroma after CXL-TE at 3<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>, probably due to the lower power used in the latter technique.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Ultimately, nerve fibres regenerate completely 12 months after CXL, maintaining neurotrophism, corneal sensitivity and tear reflex.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,16</span></a></p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Effects of ultraviolet light</span><p id="par0030" class="elsevierStylePara elsevierViewall">UV light with a wavelength (λ) of 200−400<span class="elsevierStyleHsp" style=""></span>nm (nanometres) is a major stress factor for microorganisms and is used in multiple medical and non-medical applications for disinfection.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> The ATM mechanism of action of UV light is DNA damage secondary to the direct absorption of photons by nucleic acids or the release of reactive oxygen species through a reaction with a photosensitising chemical substrate in the presence of oxygen. UV-C light with an λ of 200−280<span class="elsevierStyleHsp" style=""></span>nm and UV-B light with anλ of 280−320<span class="elsevierStyleHsp" style=""></span>nm can directly inactivate microorganisms by affecting the integrity of their DNA, while UV-A light with an λ of 320−400<span class="elsevierStyleHsp" style=""></span>nm generates reactive oxygen species in the presence of a photosensitiser, RB, which can damage multiple targets within the same cell, including proteins and nucleic acids, thereby killing microorganisms.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> However, due to the paucity of adequate clinical data reported in the scientific literature, it is difficult to reach a consensus on an effective and safe dose of UV light that can be applied in an IK.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> An <span class="elsevierStyleItalic">in vitro</span> study highlighted that a single dose of 1.93<span class="elsevierStyleHsp" style=""></span>mJ/cm<span class="elsevierStyleSup">2</span> of UV-C light was effective in inhibiting the growth of different bacteria, while a dose of 57.9<span class="elsevierStyleHsp" style=""></span>mJ/cm<span class="elsevierStyleSup">2</span> did not compromise the feasability of cultured human corneal epithelial cells. In the knowledge of the authors, this is the only study that has evaluated the safety of UV ATM dose.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Influence of PACK-CXL energy on microbial death rate</span><p id="par0035" class="elsevierStylePara elsevierViewall">PACK-CXL follows the Bunsen-Roscoe law, where an increase in fluence (J/cm<span class="elsevierStyleSup">2</span>) does not necessarily imply a longer treatment duration, but could be achieved with a higher UV light irradiance (mW/cm<span class="elsevierStyleSup">2</span>).<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> In the work of Kling et al.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> it was shown that the degree of bacterial death was dependent on the UV-A energy, but not on the irradiation time, as previously demonstrated in a work by Bäckman et al.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> Said authors observed that increasing the UV-A light irradiation energy to 16.2<span class="elsevierStyleHsp" style=""></span>J/cm<span class="elsevierStyleSup">2</span> (corresponding to 18<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>, for 15<span class="elsevierStyleHsp" style=""></span>min or more) would probably kill 100% of <span class="elsevierStyleItalic">Staphylococcus aureus-type</span> bacteria at a concentration of 10<span class="elsevierStyleSup">4</span> bacteria/mL.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> In addition, Kling et al. observed that the bacterial kill ratio with PACK-CXL was significantly reduced in larger irradiated volumes and was probably due to lower UV-A intensity in deeper layers and a higher absolute number of surviving bacteria.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> These authors also observed that higher treatment efficacy at higher volumes required higher UV energy (on average 3.8% per J/cm<span class="elsevierStyleSup">2</span>). Interestingly, ATB-resistant strains had similar susceptibility in terms of bacterial death compared to non-resistant bacteria.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">It is important to note that the UV-A light dose delivered during a conventional CXL technique is 25 times higher than 216<span class="elsevierStyleHsp" style=""></span>mJ/cm<span class="elsevierStyleSup">2</span>, which is the value at which DNA strand breaks have been demonstrated in porcine corneal epithelial cells.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> It was therefore essential to make safety estimates of the corneal endothelium, lens and retina during and after CXL for higher UV light energies.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> These were initially done by concluding that corneas should be at least 400<span class="elsevierStyleHsp" style=""></span>μ thick for an irradiance of 5.4<span class="elsevierStyleHsp" style=""></span>J/cm<span class="elsevierStyleSup">2</span>.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,18</span></a> However, new studies with higher UV energy, 7.2 and 18<span class="elsevierStyleHsp" style=""></span>J/cm<span class="elsevierStyleSup">2</span>, did not observe endothelial alterations.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19,20</span></a> In addition, the concentration of RB in the endothelium has been shown to be 1.7 lower than the theoretical estimate, suggesting that the threshold for UV light damage previously defined for the corneal endothelium may be too conservative, which may allow for a larger energy margin when using PACK-CXL.<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21,22</span></a> In addition, infectious corneal ulcer areas are less transparent and thicker than normal corneal tissue, which would justify higher UV energy as long as the irradiation is focused exclusively on the ulcer.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Treatment protocols</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">PACK-CXL standard and variations thereof</span><p id="par0045" class="elsevierStylePara elsevierViewall">All studies in the systematic review by Marasini et al. applied similar treatment protocols and with a UV light dose intensity of 3<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> The mode of administration of 0.1% RB with 20% dextran was every 2<span class="elsevierStyleHsp" style=""></span>min for a period of 30<span class="elsevierStyleHsp" style=""></span>min and then every 5<span class="elsevierStyleHsp" style=""></span>min for another 30<span class="elsevierStyleHsp" style=""></span>min during UV-A irradiation.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4,11,12</span></a> One study showed that an optimisation of the protocol parameters made it possible to reduce the treatment time without affecting the destruction rate of the bacterial strains.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> Price et al.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> evaluated the efficacy of UV-A exposure durations of 15, 30 and 45<span class="elsevierStyleHsp" style=""></span>min in the presence of RB and reported that the procedure was safe, except in a previous herpes simplex virus infection, in which the infection recurred. The procedure was most effective in infections that did not extend deep into the cornea.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Prajna et al. performed a CXL technique with a modified Dresden protocol, in which the epithelium around the ulcer was removed, followed by administration of UV-A light at 3<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>,<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> and although the benefit of PACK-CXL for the primary treatment of moderate bacterial keratitis (BK) could not be confirmed, PACK-CXL may reduce culture positivity and complication rates.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Kasetsuwan et al. did not remove the epithelium because according to the authors epithelial defects already existed in the ulcers. These authors concluded that standard treatment with PACK-CXL provided no benefit over standard treatment in moderate to severe IK over a 30-day period.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">PACK-CXL accelerated</span><p id="par0050" class="elsevierStylePara elsevierViewall">Accelerated PACK-CXL with modifications with respect to pathogen type in order to maintain an adequate microbial mortality rate could be as effective as the standard Dresden protocol (3<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span> for 30<span class="elsevierStyleHsp" style=""></span>min).<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> Tabibian et al. treated a case of <span class="elsevierStyleItalic">Aureobasidium pullulans</span> with PACK-CXL (9<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>, for 10<span class="elsevierStyleHsp" style=""></span>min), achieving total eradication of the infiltrate without topical ATB administration, in addition to complete closure of the corneal epithelium after 3 days.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> Famose, in his work in dogs and cats, demonstrated <span class="elsevierStyleItalic">in vitro</span> that the antibacterial efficacy of PACK-CXL was preserved using an accelerated PACK-CXL protocol (30<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>, for 3<span class="elsevierStyleHsp" style=""></span>min), observing satisfactory results in cases of IK with corneal dissolution.<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">26,27</span></a> Richoz et al. demonstrated <span class="elsevierStyleItalic">in vitro</span> that accelerated protocols of 18<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span> for 5<span class="elsevierStyleHsp" style=""></span>min and 36<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span> for 2.5<span class="elsevierStyleHsp" style=""></span>min had similar kill rates (approximately 93%) for <span class="elsevierStyleItalic">Staphylococcus aureus</span> and <span class="elsevierStyleItalic">Pseudomonas aeruginosa compared</span> to the Dresden protocol.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> In the work of Knyazer et al., PACK-CXL (accelerated protocol, 30<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span> for 3<span class="elsevierStyleHsp" style=""></span>min) was compared together with topical ATBs versus topical ATBs in monotherapy, in patients with BK.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> In addition, the treatment costs of both groups were analysed. The authors observed faster re-epithelialisation time, shorter hospitalisations, fewer follow-up visits and a significant reduction in the need for urgent PPQ in the PACK-CXL group, but no significant differences in cost.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> The authors consider that this treatment modality could have important implications for healthcare in the context of developing countries and raise it as an interesting avenue for future research.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> In this context of underdeveloped regions, which typically have a high prevalence of BK, it is worth considering the potential advantages of PACK-CXL, offering the alternative of a single, short course of therapy, given that it is very difficult to maintain a regimen of frequent visits and proper adherence to treatment in such a context.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">PACK-CXL in bacterial infections</span><p id="par0055" class="elsevierStylePara elsevierViewall">Several studies have shown that PACK-CXL improved BK healing and blocked the progression of corneal thinning and perforation.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Two systematic reviews of PACK-CXL have been published, which together included two RCTs.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">29,30</span></a> However, since these systematic reviews were published, other RCTs of PACK-CXL have been conducted. In a recent Cochrane review that focused primarily on the management of BK using papers comparing PACK-CXL in conjunction with standard therapy versus standard therapy in monotherapy.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Two RCTs<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18,31</span></a> and one quasi-randomised controlled trial<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">32</span></a> were included. The studies included in the Cochrane review were highly variable with respect to outcome reporting and follow-up times.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Clinical heterogeneity in reported outcomes made it difficult to compare data between RCTs. In addition, there was a wide range of follow-up times: from 14 to 120 days (time to healing).<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> The most significant limitation was that the studies provided insufficient information to assess cases of BK.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Two of the 3 studies included keratitis of any etiology, but did not report results based on etiology.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Ultimately, the authors of this Cochrane review concluded that there was insufficient evidence to support PACK-CXL combination therapy in conjunction with topical ATBs as a safe and effective treatment for BK.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> However, the 5 RCTs currently underway may provide better answers in the next update of this review.<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">33–37</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Papaionnaou et al.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> evaluated a total of 25 studies in their systematic review, 2 of which are studies previously included in the Cochrane review,<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> and concluded that PACK-CXL was more effective in cases of BK (87.2% cured out of 167 eyes), but again the evidence was low because of the high number of non-randomised studies included.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Makdoumi et al. conducted a prospective study (non-randomised clinical trial) with 16 patients with a clinical diagnosis of BK, in which none of them received ATB treatment prior to inclusion in the study, with the aim of investigating PACK-CXL as a primary therapy for BKs.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> This group observed that all eyes responded to PACK-CXL with improvement of symptoms and signs with respect to reduction of inflammation and healing of the epithelial defect in all cases.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> They observed that 16 patients with BK without prior ATB treatment underwent standard PACK-CXL (Dresden protocol; 3<span class="elsevierStyleHsp" style=""></span>mW/cm<span class="elsevierStyleSup">2</span>, 30<span class="elsevierStyleHsp" style=""></span>min)<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a>; 15 patients had complete epithelial closure and all showed signs of improvement and reduced inflammatory response to bacteria.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> Two participants required ATB treatment due to poor healing secondary to underlying systemic disease (diabetes with ocular complications) or recurrent epithelial defects.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> Ultimately, the authors concluded that PACK-CXL may have potential for the cure of patients with BK.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">The systematic review by Marasini et al. observed that 2 of 5 RCT (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>27), 2 of 4 non-RCT (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>25) and 17 of 22 case studies (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58) evaluated PACK-CXL as a last chance to preserve corneal integrity in recalcitrant infections that did not respond to standard medical treatment.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> However, despite the fact that CXL has shown efficacy in corneal ectasia in halting progression by improving the biomechanical stability of the uninfected cornea, the review by Marasini et al. observed that infected corneas that underwent PACK-CXL perforated or required enucleation in 15% of cases in RCTs, 0% of cases in included non-RCT studies and 12% of patients described in case series.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">A meta-analysis by Ting et al. included 46 studies, of which 4 were RCTs, with 435 patients in total.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Compared to standard ATB monotherapy, adjuvant PACK-CXL in BC resulted in a shorter mean time to complete corneal healing and faster resolution of the infiltrate at both 1 week and 1 month, with no significant difference found in epithelial defect size, best corrected visual acuity and risk of adverse events.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> This review included 4 RCTs with 58 participants in the intervention group (PACK-CXL with standard TMJ therapy) and 57 participants in the control group (standard TMJ therapy).<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The majority of the studies focused on either KCs, fungal keratitis (FK) or a combination of both, and only one RCT included <span class="elsevierStyleItalic">Acanthamoeba</span> keratitis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> No RCT examined the usefulness of PACK-CXL in viral keratitis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> PACK-CXL was superior to ATM therapy in the resolution of infiltrate size at 7 days and at the end of follow-up (14–30 days).<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,29</span></a> PACK-CXL did not reduce the risk of adverse events such as corneal perforation when compared to the ATM therapy alone group.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Three RCTs<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18,31,32</span></a> showed a similar or lower risk of adverse effects in the PACK-CXL group. However, Uddaraju et al.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> observed an opposite trend. Overall, the evidence was of very low quality, with insufficient sample size in the 4 RCTs to achieve sufficient power in terms of efficacy and safety outcomes.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Price et al.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> and Hafezi and Randleman.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">40</span></a> previously estimated that 200–250 participants are needed to assess the efficacy of PACK-CXL, far short of the number of participants in the RCTs in this meta-analysis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The other limitation was the inconsistency in measurement and reporting of treatment outcomes among the 4 included RCTs, reporting 8 different outcomes.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> In addition, the risk of adverse events was the only outcome that was systematically examined across the 4 RCTs.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Ultimately, this meta-analysis demonstrates that adjuvant PACK-CXL accelerates healing of IK compared to ATM therapy alone, with low quality evidence. Therefore, it shows that more high-quality and adequately powered RCTs are needed to fully determine the therapeutic effect of PACK-CXL.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">Prajna et al. noted that no benefit of adjuvant CXL in the primary treatment of BKs could be demonstrated.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> However, they did observe that the CXL group was less likely to have positive cultures at 24<span class="elsevierStyleHsp" style=""></span>h than patients in the group given topical moxifloxacin (0.5%).<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Bamdad et al. demonstrated that patients who received CXL and ATB, relative to those in the ATB monotherapy group (topical moxifloxacin 0.5%/h), had a smaller area of epithelial defect, a smaller area of infiltration and a shorter mean duration of treatment.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">In the work of Kasetsuwan et al. they observed that standard combined treatment with PACK-CXL in moderate to severe KC and FK did not provide any benefit over standard treatment alone.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> No significant differences in the size of infiltrates or epithelial defects were observed.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Achiron et al. in their study compared PACK-CXL in combination with standard ATB therapy (26 eyes) to standard ATB therapy alone (21 eyes) in patients with moderate and severe KCB. The authors demonstrated that the combined treatment reduces healing time, improves final visual acuity (VA) and reduces the need for tectonic keratoplasty.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">41</span></a> The authors observed that patients in the first group had more favourable results in terms of number of tectonic grafts (0% in the combined group compared to 33.3% in the standard ATB alone group), better final uncorrected VA (mean difference, compared to the standard ATB alone group, of 0.57 logMAR) and better final corrected VA (mean difference, compared to the standard ATB alone group, of 0.7 logMAR) and shorter re-epithelialisation time (mean difference of 9.63 days).<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">41</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">PACK-CXL in <span class="elsevierStyleItalic">Acanthamoeba</span> infections</span><p id="par0095" class="elsevierStylePara elsevierViewall">Four in vitro studies evaluated the impact of UV radiation on <span class="elsevierStyleItalic">Acanthamoeba</span> isolated from corneal ulcers, and reported that the method was ineffective in inhibiting their proliferation,<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">42–45</span></a> while the same treatment, at similar doses, was shown to be effective in some patients.<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">46–48</span></a> However, in the meta-analysis by Ting et al. the evidence on the use of PACK-CXL in <span class="elsevierStyleItalic">Acanthamoeba</span> keratitis and mixed keratitis (MK) was insufficient.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">PACK-CXL in fungal infections</span><p id="par0100" class="elsevierStylePara elsevierViewall">Management of fungal keratitis (FK) is challenging and recurrence of infection can be observed even after keratoplasty (KP).<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> Deep corneal vascularisation is a high-risk factor affecting graft survival and optical Pk is often necessary after “warm” Pk to obtain satisfactory visual rehabilitation.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> CXL in Boston keratoprosthesis donor corneas results in a lower incidence of corneal dissolution,<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> which may be beneficial in preventing deep vascularisation<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> and may alter corneal permeability to drugs.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> Thus, the authors of this study conclude that CXL-treated donor corneas could help reduce the incidence of graft reinfection after keratoplasty in FK.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">The study by Uddaraju et al.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> included severe and refractory FK with involvement of the posterior two-thirds of the cornea and unresponsive to standard antifungal therapy during the previous 2 weeks, so the findings could be confounded by the difference in the initial severity of FK where the PACK-CXL group was much worse than the single ATM therapy group.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> Based on these findings, the authors advise against the use of PACK-CXL in severe deep FK.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">The study by Prajna et al. aims to determine if there is any benefit of PACK-CXL in filamentous FK and compares topical natamycin 5% versus topical amphotericin 0.15%.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a> Four groups were randomised: topical natamycin 5%, natamycin 5%<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PACK-CXL, amphotericin 0.15% and amphotericin 0.15%<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>PACK-CXL.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a> The results obtained were that patients assigned to the PACK-CXL group, regardless of whether they received natamycin or topical amphotericin, were 1.32 more likely to have culture positivity at 24<span class="elsevierStyleHsp" style=""></span>h, without being statistically significant, and the best corrected VA was 0.22<span class="elsevierStyleHsp" style=""></span>logMAR worse on average at 3 weeks and 0.32<span class="elsevierStyleHsp" style=""></span>logMAR worse at 3 months, among those who received PACK-CXL. No differences were observed in the size of infiltrates and/or scarring, nor in the percentage of adverse events between the groups.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a> Ultimately, there appears to be no benefit of adjuvant PACK-CXL in the treatment of filamentous FK, and may even result in a decrease in VA in the PACK-CXL group.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">The <span class="elsevierStyleItalic">Cross-Linking Assisted Infection Reduction (CLAIR)</span> RCT observed no benefit of PACK-CXL in the primary management of filamentous FK at 3 months.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a> At 12-month follow-up of the CLAIR trial,<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> the best corrected VA was 1.8<span class="elsevierStyleHsp" style=""></span>logMAR worse in the PACK-CXL group. No difference in VA was observed between those randomised to topical amphotericin 0.15% versus the topical natamycin 5% group, regardless of whether or not they underwent PACK-CXL, and no difference in ulcer infiltrate and/or scar size was observed between those who received PACK-CXL compared to those who did not.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> There were 10 patients with full-thickness corneal perforation, 4 in the PACK-CXL group and 6 in the topical medication monotherapy group.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> A total of 21 patients ended up in keratoplasty, 11 patients in the PACK-CXL group and 10 patients in the medication only group.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> In summary, at 12 months there was no benefit of PACK-CXL as an adjuvant in the treatment of filamentous FK, in terms of VA, scar size or complications, including perforation and QP.</p><p id="par0120" class="elsevierStylePara elsevierViewall">Bamdad et al. observed in their work that out of 9 patients with FK refractory to conventional treatment, 4 (2 cases caused by <span class="elsevierStyleItalic">Aspergillus</span> and 2 by <span class="elsevierStyleItalic">Fusarium</span>) had a good response to PACK-CXL, with a mean time to complete epithelialisation and a mean time to resolution of stromal infiltration of 14.25<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.38 and 22.5<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7.29 days, respectively.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a> There were no statistically significant differences between the responder and non-responder groups with respect to mean depth of infiltration and mean ulcer size.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a> The authors conclude that PACK-CXL could be added to the therapeutic arsenal of antimicrobial agents for the management of severe and refractory cases of FK.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">Recently, a phase 3 RCT has been published, where participants, with BK, FK or MF, were randomised to 2 groups (PACK-CXL vs. ATM therapy).<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a> In this work, it was observed that the success rate (defined as complete resolution of signs of infection) in the PACK-CXL group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>18) was 88.9% (16/18 patients), and 90.5% (19/21 patients) in the ATM therapy group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21).<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a> The authors conclude that PACK-CXL may be an alternative to ATM drugs for the first-line, stand-alone treatment of early to moderate BK, FK or MK.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">PACK-CXL in infectious keratitis after penetrating keratoplasty</span><p id="par0130" class="elsevierStylePara elsevierViewall">The incidence of post-PPK IK varies between 1.76%–12.1%, with a treatment failure rate in PPKs of 26%–57% (as opposed to a 10% failure rate in non-PPK IK).<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> IKs may account for 5.1%–32.3% of all indications for PPK, depending on the series.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> Due to the long-term use of topical steroids, <span class="elsevierStyleItalic">Staphylococcus</span> and <span class="elsevierStyleItalic">Candida</span> are the main causes of post-PPK IKs.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> In the work of Uzman et al. a higher, but not statistically significant, rate of resolution of BK and QF infiltrates was observed in the PACK-CXL group combined with TMJ therapy (83.3%) compared to the control group, which received TMJ therapy alone (68.2%).<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> In addition, they observed that the infiltrates did not resolve after PACK-CXL in 2 patients with BK and 1 patient with FK, both of whom had full-thickness corneal stroma involvement.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> The results of Uzman et al. show that the depth of the infiltrate is more important than the type of pathogen, with a 25% resolution rate observed in cases of total corneal involvement with endothelial plaque,<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> so that the response to treatment with PACK-CXL seems to be better in early IK, when the infection only affects the superficial layers of the corneal stroma<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a>; this could be explained because the effect of CXL with Dresden protocol is limited to the anterior 300<span class="elsevierStyleHsp" style=""></span>μ of the stroma.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> Ultimately, PACK-CXL demonstrated a shorter healing time and a higher proportion of patients with at least 2 lines of visual improvement compared to the group treated with antimicrobial therapy alone.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Infectious keratitis post-CXL</span><p id="par0135" class="elsevierStylePara elsevierViewall">Although CXL has been used for the management of IK, these infections can occur postoperatively with this same technique.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> Among the main causes described are the presence of an epithelial defect, the use of contact lenses and/or topical steroids in the immediate postoperative period.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> In the case of IK post-CXL, microbial invasion is likely to occur during the postoperative period rather than during surgery, as this technique not only damages keratocytes but also kills bacteria and fungi.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> In an open-label comparative clinical trial, Tzamalis et al. found that delaying the use of topical steroids until the epithelium healed reduced the likelihood of infection.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> In the work of Khoo et al. more than 70% of patients had worn contact lenses within one month prior to infection.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> However, due to the study design it could not be determined whether the use of a contact lens, a topical steroid or their combination leads to an increase in infection.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> The CXL <span class="elsevierStyleItalic">epi-off</span> technique is itself a predisposing risk factor for IK because of the epithelial defect resulting from the technique, which can take 2–5 days to heal and is an important entry point for microorganisms.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> The organisms described as causing post-CXL IK range from bacteria to herpes simplex virus, fungi and even <span class="elsevierStyleItalic">Acanthamoeba</span>.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> In the work of Khoo et al. 42% of the causative organisms were coagulase negative staphylococci.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> While it is true that CXL may have ATM activity, it may also alter the normal ocular flora, and thus secondarily increase the risk of infection, especially when the corneal epithelium is compromised.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a></p></span></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conclusions</span><p id="par0140" class="elsevierStylePara elsevierViewall">PACK-CXL could serve as a useful therapeutic arsenal to complete healing and reduce the size of the infiltrate in IK<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> but we should note that, to our knowledge, there are no studies (including <span class="elsevierStyleItalic">in vitro</span> studies) that have evaluated the safety of the treatment with respect to its potential genotoxicity, i.e. its ability to induce mutations in cellular genetic information.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Adjustments of CXL treatment parameters, as well as the duration of irradiation and energy used, could help increase the efficacy of PACK-CXL depending on the type of pathogen.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> The timing of initiating PACK-CXL could be chosen according to the clinical evolution of the patients, but it is recommended, following current evidence, that PACK-CXL be performed one week after the start of medical treatment in non-responder patients.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">The authors of the Cochrane review concluded that there was insufficient evidence to support PACK-CXL combined therapy with topical ATBs as a safe and effective treatment for BK.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> However, Papaionnaou et al.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> and Ting et al.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> concluded that PACK-CXL was more effective in cases of BK (87.2% cured out of 167 eyes)<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> and had a shorter mean time to complete corneal healing and faster resolution of the infiltrate,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> although the evidence was low due to the high number of non-randomised studies included.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,30</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">The SCUT II study protocol has recently been published, where the authors hope that the results of this work will provide evidence of the efficacy of PACK-CXL and early steroids as adjunctive treatments in KC.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> The authors anticipate that these therapies will improve outcomes such as VA, while reducing the rate of complications such as corneal perforation or the need for therapeutic PK.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall">Current evidence on the use of PACK-CXL is insufficient for the recommendation of this technique in <span class="elsevierStyleItalic">Acanthamoeba</span> keratitis and MK.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Furthermore, in viral keratitis, PACK-CXL is contraindicated because of the possibility of exacerbating or activating herpes simplex virus infection.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,24,55</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">Following the conclusions of the CLAIR study, there appears to be no benefit of adjuvant PACK-CXL in the treatment of filamentous FK either at 3 or 12 months follow-up, and it may even produce a decrease in VA in the PACK-CXL group.<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">50,51</span></a> However, Bamdad et al. recommend the use of PACK-CXL in cases of refractory FK to avoid emergency PCI.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">In summary, the current evidence on the effectiveness of PACK-CXL for the management of IK appears to be low, clinically heterogeneous in terms of outcomes<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> and with questionable safety in certain etiologies. Currently, there are 5 ongoing RCTs<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">33–37</span></a> with 1136 participants, which will hopefully provide more specific and clarifying answers.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflicts of interest</span><p id="par0170" class="elsevierStylePara elsevierViewall">No conflicts of interest were declared by the authors.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres1751653" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1542804" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1751654" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1542805" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Methodology" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Corneal cross-linking" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Post-CXL neurotoxicity" ] ] ] 7 => array:2 [ "identificador" => "sec0025" "titulo" => "Effects of ultraviolet light" ] 8 => array:2 [ "identificador" => "sec0030" "titulo" => "Influence of PACK-CXL energy on microbial death rate" ] 9 => array:3 [ "identificador" => "sec0035" "titulo" => "Treatment protocols" "secciones" => array:7 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "PACK-CXL standard and variations thereof" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "PACK-CXL accelerated" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "PACK-CXL in bacterial infections" ] 3 => array:2 [ "identificador" => "sec0055" "titulo" => "PACK-CXL in Acanthamoeba infections" ] 4 => array:2 [ "identificador" => "sec0060" "titulo" => "PACK-CXL in fungal infections" ] 5 => array:2 [ "identificador" => "sec0065" "titulo" => "PACK-CXL in infectious keratitis after penetrating keratoplasty" ] 6 => array:2 [ "identificador" => "sec0070" "titulo" => "Infectious keratitis post-CXL" ] ] ] 10 => array:2 [ "identificador" => "sec0075" "titulo" => "Conclusions" ] 11 => array:2 [ "identificador" => "sec0080" "titulo" => "Conflicts of interest" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2021-10-30" "fechaAceptado" => "2022-02-02" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1542804" "palabras" => array:4 [ 0 => "Infectious keratitis" 1 => "Corneal cross-linking" 2 => "PACK-CXL" 3 => "Corneal ulcer" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1542805" "palabras" => array:4 [ 0 => "Queratitis infecciosas" 1 => "Cross-linking corneal" 2 => "PACK-CXL" 3 => "Úlcera corneal" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Infectious keratitis (IK) is one of the most common causes of monocular blindness worldwide, especially in developing countries and may account for 5.1%–32.3% of all indications for penetrating keratoplasty (PK). However, performing a therapeutic PK on a “hot eye” is associated with a higher incidence of IK recurrence and graft rejection. Standard treatment includes antimicrobials (ATM) and, once the causative pathogen has been identified, must be continued with targeted treatment, depending on antibiogram sensitivity. However, appearance of multiresistant strains to ATM is progressively increasing at an alarming rate. Besides that, the diversity of the causative microorganisms (bacteria, fungi, parasites, viruses) may hinder the clinical diagnosis and secondarily the proper treatment from the beginning. It is estimated that only 50% of eyes will have a good visual result if the correct therapy is delayed. All these factors make the identification of alternatives to ATM treatment of paramount importance. Due to the ATM properties of photoactivated chromophore (riboflavin, RB) and ultraviolet (UV) light of wavelength (λ) 200–400 nanometers (nm), used in multiple medical and non-medical applications for disinfection, photoactivated chromophore for corneal cross-linking (CXL) of IK (PACK-CXL), as an addition to the therapeutic arsenal for the management of IK has been proposed. It must be differentiated from CXL used for the management of progressive keratoconus (KC). The objective of this review is to update the available evidence on the efficacy and safety of PACK-CXL in IKs.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Las queratitis infecciosas (QI) es una de las causas más comunes de ceguera a nivel mundial, especialmente en países en vías de desarrollo y puede llegar a representar del 5.1% al 32.3% de todas las indicaciones de queratoplastia penetrante (QPP). Sin embargo, realizar una queratoplastia terapéutica en “caliente” está asociado con una mayor incidencia de recurrencia de la QI y rechazo del injerto. El tratamiento estándar incluye antimicrobianos (ATM) de amplio espectro y, una vez identificado el patógeno causante y el antibiograma, continuar con un tratamiento dirigido, según la sensibilidad del germen. La aparición de cepas multirresistentes a los ATM está aumentando progresivamente a un ritmo alarmante en los últimos tiempos. Asimismo, la diversidad de los microorganismos causantes (bacterias, hongos, parásitos, virus) dificultan en ocasiones la realización de diagnóstico clínico correcto, retrasando en inicio de un tratamiento efectivo. Se estima que sólo un 50% de los ojos tendrá un buen resultado visual si se retrasa la terapia. En definitiva, todos estos factores hacen que sea muy importante la identificación de alternativas al tratamiento ATM. Por las propiedades ATM del cromóforo fotoactivado (riboflavina, RB) y la luz ultravioleta (UV) de longitud de onda (λ) 200−400 nanómetros (nm), utilizada en múltiples aplicaciones médicas y no médicas para la desinfección, se ha propuesto el cromóforo fotoactivado para el cross-linking (CXL) corneal en el tratamiento de las QI (por sus siglas en inglés, PACK-CXL), como una herramienta adicional en el arsenal terapéutico de las QI. Debe diferenciarse del CXL empleado para el manejo del queratocono (QC) progresivo. El objetivo de esta revisión es actualizar la evidencia disponible sobre la eficacia y seguridad de PACK-CXL en las QI.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Hamida Abdelkader SM, Rodríguez Calvo-de-Mora M, Gegúndez-Fernández JA, Soler-Ferrández FL, Rocha-de-Lossada C. Revisión de la literatura sobre la evidencia disponible actualmente para el manejo de las queratitis infecciosas con PACK-CXL. Arch Soc Esp Oftalmol. 2022;97:464–472.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:55 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photoactivated chromophore for infectious keratitis–Corneal cross-linking (PACK-CXL): a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.S.J. Ting" 1 => "C. Henein" 2 => "D.G. Said" 3 => "H.S. Dua" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ocul Surf." "fecha" => "2019" "volumen" => "17" "paginaInicial" => "624" "paginaFinal" => "634" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High fluence increases the antibacterial efficacy of PACK cross-linking" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Kling" 1 => "F.S. Hufschmid" 2 => "E.A. Torres-Netto" 3 => "J.B. Rendleman" 4 => "M. Willcox" 5 => "Zbinden" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ICO.0000000000002335" "Revista" => array:6 [ "tituloSerie" => "Cornea." "fecha" => "2020" "volumen" => "39" "paginaInicial" => "1020" "paginaFinal" => "1026" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32304431" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photoactivated chromophore for moderate to severe infectious keratitis as an adjunct therapy: a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Kasetsuwan" 1 => "U. Reinprayoon" 2 => "A.V. Satitpitakul" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ajo.2016.02.030" "Revista" => array:6 [ "tituloSerie" => "Am J Ophthalmol." "fecha" => "2016" "volumen" => "165" "paginaInicial" => "94" "paginaFinal" => "99" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26949133" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of UV application for superficial infections in humans: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Marasini" 1 => "A.C. Zhang" 2 => "S.J. Dean" 3 => "S. Swift" 4 => "J.P. Craig" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jtos.2021.03.002" "Revista" => array:6 [ "tituloSerie" => "Ocul Surf." "fecha" => "2021" "volumen" => "21" "paginaInicial" => "331" "paginaFinal" => "344" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33812086" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Double-masked, sham and placebo- controlled trial of corneal cross-linking and topical difluprednate in the treatment of bacterial keratitis: Steroids and Cross-linking for Ulcer Treatment Trial (SCUT II) study protocol" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Radhakrishnan" 1 => "V.N. Prajna" 2 => "L.S. Prajna" 3 => "A. Venugopal" 4 => "S. Narayana" 5 => "R. Rajaraman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "BMJ Open Ophthalmol." "fecha" => "2021" "volumen" => "6" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endophthalmitis in advanced microbial keratitis: risk factors and examination findings" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K.L. Christopher" 1 => "C.L. Hood" 2 => "S.I. Mian" 3 => "B. Ayres" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ICO.0000000000002349" "Revista" => array:6 [ "tituloSerie" => "Cornea." "fecha" => "2020" "volumen" => "39" "paginaInicial" => "1096" "paginaFinal" => "1101" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32472790" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantitative ocular ultrasound findings in microbial keratitis-associated endophthalmitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N. Viruni" 1 => "A.Y. Zhang" 2 => "X. Wang" 3 => "J.T. Handa" 4 => "T.Y.A. Tiu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.oret.2020.01.006" "Revista" => array:6 [ "tituloSerie" => "Ophthalmol Retina." "fecha" => "2020" "volumen" => "4" "paginaInicial" => "560" "paginaFinal" => "567" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32147489" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapeutic and optical keratoplasty in the management of Acanthamoeba keratitis: risk factors, outcomes, and summary of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D. Robaei" 1 => "N. Carnt" 2 => "D.C. Minassian" 3 => "J.K.G. Dart" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ophtha.2014.07.052" "Revista" => array:7 [ "tituloSerie" => "Ophthalmology." "fecha" => "2015" "volumen" => "122" "paginaInicial" => "17" "paginaFinal" => "24" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25262318" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673604170189" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term functional and anatomic outcomes of repeat graft after optically failed therapeutic keratoplasty" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D. Srujana" 1 => "M. Kaur" 2 => "J. Urkude" 3 => "Rathi Anubha" 4 => "N. Sharma" 5 => "J.S. Titiyal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ajo.2018.03.011" "Revista" => array:6 [ "tituloSerie" => "Am J Ophthalmol." "fecha" => "2018" "volumen" => "189" "paginaInicial" => "166" "paginaFinal" => "175" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29550189" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Repeat keratoplasty for failed therapeutic keratoplasty for microbial keratitis: an analysis of characteristics and risk factors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Wan" 1 => "J. Lin" 2 => "Y. Hu" 3 => "Wei Menghuan" 4 => "Y. Zou" 5 => "Z. Yuan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "J Ophthalmol." "fecha" => "2020" "volumen" => "2020" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photoactivated chromophore for keratitis-corneal collagen cross-linking (PACK-CXL) improves outcomes of treatment-resistant infectious keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R.G. Cañizo" 1 => "A. Benatti" 2 => "G. De Wit-Carter" 3 => "E. Hernández-Quintela" 4 => "V. Sánchez-Huerta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/OPTH.S284306" "Revista" => array:6 [ "tituloSerie" => "Clin Ophthalmol." "fecha" => "2020" "volumen" => "14" "paginaInicial" => "4451" "paginaFinal" => "4457" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33376299" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cross-Linking Assisted Infection Reduction (CLAIR): a randomized clinical trial evaluating the effect of adjuvant cross-linking on bacterial keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.V. Prajna" 1 => "N. Radhakrishnan" 2 => "P. Lalitha" 3 => "R. Rajaraman" 4 => "S. Narayana" 5 => "A.F. Austin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ICO.0000000000002510" "Revista" => array:6 [ "tituloSerie" => "Cornea." "fecha" => "2021" "volumen" => "40" "paginaInicial" => "837" "paginaFinal" => "841" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33079921" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Accelerated corneal cross-linking as an adjunct therapy in the management of presumed bacterial keratitis: a cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Knyazer" 1 => "Y. Krakauer" 2 => "M. Abu Tailakh" 3 => "A. Achiron" 4 => "I. Hecht" 5 => "T. Lifshitz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3928/1081597X-20200226-02" "Revista" => array:6 [ "tituloSerie" => "J Refract Surg." "fecha" => "2020" "volumen" => "36" "paginaInicial" => "258" "paginaFinal" => "264" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32267957" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PACK-CXL: corneal cross-linking in infectious keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Tabibian" 1 => "C. Mazzotta" 2 => "F. Hafezi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s40662-016-0042-x" "Revista" => array:5 [ "tituloSerie" => "Eye Vis (Lond)." "fecha" => "2016" "volumen" => "3" "paginaInicial" => "11" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27096139" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "In vivo confocal microscopy after corneal collagen cross-linking" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Mazzotta" 1 => "F. Hafezi" 2 => "G. Kymionis" 3 => "S. Caragiuli" 4 => "S. Jacob" 5 => "C. Traversi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jtos.2015.04.007" "Revista" => array:6 [ "tituloSerie" => "Ocul Surf." "fecha" => "2015" "volumen" => "13" "paginaInicial" => "298" "paginaFinal" => "314" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26142059" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Collagen cross-linking in keratoconus in Asian eyes: visual, refractive and confocal microscopy outcomes in a prospective randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Sharma" 1 => "K. Suri" 2 => "S.V. Sehra" 3 => "J.S. Titiyal" 4 => "R. Sinha" 5 => "R. Tandon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10792-015-0054-x" "Revista" => array:6 [ "tituloSerie" => "Int Ophthalmol." "fecha" => "2015" "volumen" => "35" "paginaInicial" => "827" "paginaFinal" => "832" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25708282" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The efficiency of cross-linking methods in eradication of bacteria is influenced by the riboflavin concentration and the irradiation time of ultraviolet light" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Bäckman" 1 => "K. Makdoumi" 2 => "J. Mortensen" 3 => "S. Crafoord" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Ophthalmol (Copenh)." "fecha" => "2014" "volumen" => "92" "paginaInicial" => "656" "paginaFinal" => "661" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultraviolet A/riboflavin collagen cross- linking for treatment of moderate bacterial corneal ulcers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Bamdad" 1 => "H. Malekhosseini" 2 => "A. Khosravi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ICO.0000000000000375" "Revista" => array:6 [ "tituloSerie" => "Cornea." "fecha" => "2015" "volumen" => "34" "paginaInicial" => "402" "paginaFinal" => "406" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25710507" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Toric topographically customized transepithelial, pulsed, very high-fluence, higher energy and higher riboflavin concentration collagen cross-linking in keratoconus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.J. Kanellopoulos" 1 => "W.J. Dupps" 2 => "I. Seven" 3 => "G. Asimellis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000363371" "Revista" => array:6 [ "tituloSerie" => "Case Rep Ophthalmol." "fecha" => "2014" "volumen" => "5" "paginaInicial" => "172" "paginaFinal" => "180" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25076897" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Customized corneal cross-linking: one-year results" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "T.G. Seiler" 1 => "I. Fischinger" 2 => "T. Koller" 3 => "D. Zapp" 4 => "B.E. Frueh" 5 => "T. Seiler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ajo.2016.02.029" "Revista" => array:6 [ "tituloSerie" => "Am J Ophthalmol." "fecha" => "2016" "volumen" => "166" "paginaInicial" => "14" "paginaFinal" => "21" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26944278" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Riboflavin concentrations at the endothelium during corneal cross-linking in humans" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "T.G. Seiler" 1 => "A. Batista" 2 => "B.E. Frueh" 3 => "K. Koenig" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Invest Ophth Vis Sci." "fecha" => "2019" "volumen" => "60" "paginaInicial" => "2140" "paginaFinal" => "2145" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Microbial keratitis after corneal collagen cross-linking for corneal ectasia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Khoo" 1 => "M. Cabrera-Aguas" 2 => "S.L. Watson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Asia Pac J Ophhtalmol (Phila)." "fecha" => "2021" "volumen" => "10" "paginaInicial" => "355" "paginaFinal" => "359" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibacterial efficacy of accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking (PACK-CXL)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Richoz" 1 => "S. Kling" 2 => "F. Hoogewoud" 3 => "A. Hammer" 4 => "D. Tabibian" 5 => "P. Francois" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3928/1081597X-20141118-01" "Revista" => array:7 [ "tituloSerie" => "J Refract Surg." "fecha" => "2014" "volumen" => "30" "paginaInicial" => "850" "paginaFinal" => "854" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25437485" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109711029494" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M.O. Price" 1 => "L.R. Tenkman" 2 => "A. Schrier" 3 => "K.M. Fairchild" 4 => "S.L. Trokel" 5 => "F.W. Price Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3928/1081597X-20120921-06" "Revista" => array:6 [ "tituloSerie" => "J Refract Surg." "fecha" => "2012" "volumen" => "28" "paginaInicial" => "706" "paginaFinal" => "713" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23062001" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D. Tabibian" 1 => "O. Richoz" 2 => "A. Riat" 3 => "J. Schrenzel" 4 => "F. Hafezi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3928/1081597X-20141113-06" "Revista" => array:6 [ "tituloSerie" => "J Refract Surg." "fecha" => "2014" "volumen" => "30" "paginaInicial" => "855" "paginaFinal" => "857" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25437486" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of accelerated collagen cross-linking for the treatment of melting keratitis in ten cats" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F. Famose" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/vop.12112" "Revista" => array:6 [ "tituloSerie" => "Vet Ophthalmol." "fecha" => "2015" "volumen" => "18" "paginaInicial" => "95" "paginaFinal" => "104" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24118846" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of accelerated collagen cross-linking for the treatment of melting keratitis in eight dogs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F. Famose" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/vop.12085" "Revista" => array:6 [ "tituloSerie" => "Vet Ophthalmol." "fecha" => "2014" "volumen" => "17" "paginaInicial" => "358" "paginaFinal" => "367" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23902524" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corneal collagen cross-linking for bacterial infectious keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S.A. Davis" 1 => "R. Bovelle" 2 => "G. Han" 3 => "J. Kwagyan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/14651858.CD003870.pub7" "Revista" => array:4 [ "tituloSerie" => "Cochrane Database Syst Rev." "fecha" => "2020" "volumen" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35679121" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corneal cross linking and infectious keratitis: a systematic review with a meta- analysis of reported cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.L. Alio" 1 => "A. Abbouda" 2 => "D.D. Valle" 3 => "J.M.B. Del Castillo" 4 => "J.A. Gegúndez-Fernández" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1869-5760-3-7" "Revista" => array:5 [ "tituloSerie" => "J Ophthalmic Inflamm Infect." "fecha" => "2013" "volumen" => "3" "paginaInicial" => "7" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23514443" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corneal collagen cross-linking for infectious keratitis: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Papaioannou" 1 => "M. Miligkos" 2 => "M. Papathanassiou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ICO.0000000000000644" "Revista" => array:6 [ "tituloSerie" => "Cornea." "fecha" => "2016" "volumen" => "35" "paginaInicial" => "62" "paginaFinal" => "71" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26509768" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photoactivated chromophore for moderate to severe infectious keratitis as an adjunct therapy: a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Kasetsuwan" 1 => "U. Reinprayoon" 2 => "V. Satitpitakul" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ajo.2016.02.030" "Revista" => array:6 [ "tituloSerie" => "Am J Ophthalmol." "fecha" => "2016" "volumen" => "165" "paginaInicial" => "94" "paginaFinal" => "99" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26949133" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal disolución" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.G. Said" 1 => "M.S. Elalfy" 2 => "Z. Gatzioufas" 3 => "E.S. El-Zakzouk" 4 => "M.A. Hassan" 5 => "M.Y. Saif" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ophtha.2014.01.011" "Revista" => array:6 [ "tituloSerie" => "Ophthalmology." "fecha" => "2014" "volumen" => "121" "paginaInicial" => "1377" "paginaFinal" => "1382" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24576886" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Corneal collagen cross-linking (CXL) as an adjunct in the treatment of microbial keratitis. Available from: <a target="_blank" href="http://Anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336545">Anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336545</a>." ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Steroids and cross-linking for ulcer treatment (SCUT II). ClinicalTrials.gov. Available from: <a target="_blank" href="http://Ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30685%26username=017136">Ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30685&username=017136</a>." ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Collagen cross-linking as adjunctive treatment for corneal ulcer. ClinicalTrials.gov. Available from: <a target="_blank" href="http://Ctri.nic.in/Clinicaltrials/pmaindet2.php?trial=22937%26EncHid=%26username=17601">Ctri.nic.in/Clinicaltrials/pmaindet2.php?trial=22937&EncHid=&username=17601</a>." ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Cross-linking for corneal ulcers treatment trial (CLAIR). ClinicalTrials.gov. Available from: <a target="_blank" href="http://Clinicaltrials.gov/ct2/show/record/NCT02570321">Clinicaltrials.gov/ct2/show/record/NCT02570321</a>." ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Swiss PACK-CXL multicenter trial for the treatment of infectious keratitis. ClinicalTrials.gov. Available from: <a target="_blank" href="http://clinicaltrials.gov/ct2/show/record/NCT02717871">clinicaltrials.gov/ct2/show/record/NCT02717871</a>." ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K. Makdoumi" 1 => "J. Mortensen" 2 => "O. Sorkhabi" 3 => "B.E. Malmvall" 4 => "S. Crafoord" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00417-011-1754-1" "Revista" => array:6 [ "tituloSerie" => "Graefes Arch Clin Exp Ophthalmol." "fecha" => "2012" "volumen" => "250" "paginaInicial" => "95" "paginaFinal" => "102" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21874347" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corneal cross-linking as an adjuvant therapy in the management of recalcitrant deep stromal fungal keratitis: a randomized trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Uddaraju" 1 => "J. Mascarenhas" 2 => "M.R. Das" 3 => "N. Radhakrishnan" 4 => "J.D. Keenan" 5 => "L. Prajna" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Am J Ophthalmol." "fecha" => "2015" "volumen" => "160" ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PACK-CXL: defining CXL for infectious keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F. Hafezi" 1 => "J.B. Randleman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3928/1081597X-20140609-01" "Revista" => array:6 [ "tituloSerie" => "J Refract Surg." "fecha" => "2014" "volumen" => "30" "paginaInicial" => "438" "paginaFinal" => "439" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24983827" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PACK cross-linking as adjuvant therapy improves clinical outcomes in culture-confirmed bacterial keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Achiron" 1 => "O. Elhaddad" 2 => "T. Regev" 3 => "Y. Krakauer" 4 => "E. Tsumi" 5 => "F. Hafezi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Cornea." "fecha" => "2021" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.T. Kashiwabuchi" 1 => "F.R. Carvalho" 2 => "Y.A. Khan" 3 => "D. de Freitas" 4 => "A.S. Foronda" 5 => "F.E. Hirai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1167/iovs.11-8382" "Revista" => array:6 [ "tituloSerie" => "Invest Ophthalmol Vis Sci." "fecha" => "2011" "volumen" => "52" "paginaInicial" => "9333" "paginaFinal" => "9338" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22058341" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of photodynamic therapy with methylene blue on Acanthamoeba in vitro" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Mito" 1 => "T. Suzuki" 2 => "T. Kobayashi" 3 => "X. Zheng" 4 => "Y. Hayashi" 5 => "A. Shiraishi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1167/iovs.12-9828" "Revista" => array:6 [ "tituloSerie" => "Invest Ophthalmol Vis Sci." "fecha" => "2012" "volumen" => "53" "paginaInicial" => "6305" "paginaFinal" => "6313" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22918636" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.A. Del Buey" 1 => "J.A. Cristóbal" 2 => "P. Casas" 3 => "P. Goñi" 4 => "A. Clavel" 5 => "E. Mínguez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ajo.2011.07.025" "Revista" => array:6 [ "tituloSerie" => "Am J Ophthalmol." "fecha" => "2012" "volumen" => "153" "paginaInicial" => "399" "paginaFinal" => "404" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21992713" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of riboflavin/rose bengal-mediated PACK-CXL on acanthamoeba Trophozoites and Cysts in vitro" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H.T. Atalay" 1 => "F. Dogruman-Al" 2 => "F. Sarzhanov" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/02713683.2018.1501074" "Revista" => array:6 [ "tituloSerie" => "Curr Eye Res." "fecha" => "2018" "volumen" => "43" "paginaInicial" => "1322" "paginaFinal" => "1325" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30021467" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultraviolet-a light and riboflavin therapy for Acanthamoeba keratitis: a case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Garduño-Vieyra" 1 => "C.R. Gonzalez-Sanchez" 2 => "S.E. Hernandez-Da Mota" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000331707" "Revista" => array:7 [ "tituloSerie" => "Case Rep Ophthalmol." "fecha" => "2011" "volumen" => "2" "paginaInicial" => "291" "paginaFinal" => "295" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21941509" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S014067361732247X" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corneal cross-linking as supplementary treatment Option in melting keratitis: a case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Muller" 1 => "M.A. Thiel" 2 => "A.I. Kipfer-Kauer" 3 => "C. Kaufmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1055/s-0031-1299420" "Revista" => array:6 [ "tituloSerie" => "Klin Monbl Augenheilkd." "fecha" => "2012" "volumen" => "229" "paginaInicial" => "411" "paginaFinal" => "415" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22496015" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photo-activated riboflavin therapy of refractory corneal ulcers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Panda" 1 => "S.N. Krishna" 2 => "S. Kumar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ICO.0b013e31823f8f48" "Revista" => array:6 [ "tituloSerie" => "Cornea." "fecha" => "2012" "volumen" => "31" "paginaInicial" => "1210" "paginaFinal" => "1213" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22710492" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Collagen cross-linked therapeutic grafts in fungal keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.S. Titiyal" 1 => "A. Karunakaran" 2 => "M. Kaur" 3 => "A. Rathi" 4 => "T. Agarwal" 5 => "N. Sharma" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ophhtalmology." "fecha" => "2018" "volumen" => "125" "paginaInicial" => "1471" "paginaFinal" => "1473" ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cross-linking-assisted infection reduction: a randomized clinical trial evaluating the effect of adjuvant cross-linking on outcomes in fungal keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.V. Prajna" 1 => "N. Radhakrishnan" 2 => "P. Lalitha" 3 => "A. Austin" 4 => "K.J. Ray" 5 => "J.D. Keenan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ophtha.2019.08.029" "Revista" => array:6 [ "tituloSerie" => "Ophthalmology." "fecha" => "2020" "volumen" => "127" "paginaInicial" => "159" "paginaFinal" => "166" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31619359" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cross-linking assisted infection reduction: one-year follow-up of a randomized clinical trial evaluating cross-linking for fungal keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.V. Prajna" 1 => "N. Radhakrishnan" 2 => "P. Lalitha" 3 => "A. Austin" 4 => "Z. Liu" 5 => "J.D. Keenan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ophtha.2020.09.042" "Revista" => array:6 [ "tituloSerie" => "Ophthalmology." "fecha" => "2021" "volumen" => "128" "paginaInicial" => "950" "paginaFinal" => "952" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33031809" "web" => "Medline" ] ] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corneal cross-linking as an adjunct for the management of refractory fungal keratitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Bamdad" 1 => "M.R. Khalili" 2 => "A. Khosravi" 3 => "A. Attarzade" 4 => "H. Movahedan" 5 => "M. Nejabat" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4103/meajo.MEAJO_130_19" "Revista" => array:6 [ "tituloSerie" => "Middle East Afr J Ophthalmol." "fecha" => "2021" "volumen" => "27" "paginaInicial" => "204" "paginaFinal" => "209" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33814816" "web" => "Medline" ] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PACK-CXL vs. antimicrobial therapy for bacterial, fungal, and mixed infectious keratitis: a prospective randomized phase 3 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Hafezi" 1 => "M. Hosny" 2 => "R. Shetty" 3 => "B. Knyazer" 4 => "S. Chen" 5 => "Q. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s40662-021-00272-0" "Revista" => array:5 [ "tituloSerie" => "Eye Vis (Lond)." "fecha" => "2022" "volumen" => "9" "paginaInicial" => "2" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34996516" "web" => "Medline" ] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corneal collagen cross-linking with photoactivated chromophore for infectious keratitis after penetrating keratoplasty" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.O. Uzman" 1 => "Z.Y. Akkaya" 2 => "A. Burcu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ICO.0000000000002210" "Revista" => array:6 [ "tituloSerie" => "Cornea." "fecha" => "2020" "volumen" => "39" "paginaInicial" => "283" "paginaFinal" => "289" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31764287" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Herpetic keratitis with iritis after corneal crosslinking with riboflavin and ultraviolet A for keratoconus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.D. Kymionis" 1 => "D.M. Portaliou" 2 => "D.I. Bouzoukis" 3 => "L.H. Suh" 4 => "A.I. Pallikaris" 5 => "M. Markomanolakis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcrs.2007.06.036" "Revista" => array:6 [ "tituloSerie" => "J Cataract Refract Surg." "fecha" => "2007" "volumen" => "33" "paginaInicial" => "1982" "paginaFinal" => "1984" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17964410" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735794/0000009700000008/v1_202207300614/S2173579422000858/v1_202207300614/en/main.assets" "Apartado" => array:4 [ "identificador" => "5815" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735794/0000009700000008/v1_202207300614/S2173579422000858/v1_202207300614/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173579422000858?idApp=UINPBA00004N" ]
